Correction: HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo

Oncotarget. 2019 Aug 20;10(49):5120-5122. doi: 10.18632/oncotarget.27162.

Authors

Laurence Booth¹, Jane L Roberts¹, Andrew Poklepovic², Francesca Avogadri-Connors³, Richard E Cutler³, Alshad S Lalani³, Paul Dent¹

Affiliations

¹ Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA 23298, USA.
² Department of Medicine, Virginia Commonwealth University, Richmond, VA 23298, USA.
³ Puma Biotechnology Inc., Los Angeles, CA 90024, USA.

Abstract

[This corrects the article DOI: 10.18632/oncotarget.21660.].

Publication types

Published Erratum